Buy Paxlovid (Nirmatrelvir & Ritonavir) in india

 Paxlovid (Nirmatrelvir & Ritonavir)

Drug Name: Paxlovid 

Generic Name: Nirmatrelvir & Ritonavir

Dosage Forms & Strengths: Nirmatrelvir 150 mg and ritonavir 100 mg tablets

Manufactured by: Pfizer Inc

Medicinal Uses

• PAXLOVID, which consists of ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, and nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also known as 3CLpro or nsp5 protease) inhibitor, is recommended for the treatment of mild-to-moderate COVID-19 in adults who are at high risk of progressing to severe COVID-19, which may require hospitalisation or even result in death.

Recommended Dosage:

Begin PAXLOVID treatment promptly after a COVID-19 diagnosis, within 5 days of symptom onset.

Take 300 mg nirmatrelvir (two 150 mg tablets) and 100 mg ritonavir (one 100 mg tablet) together, twice daily for 5 days.

For moderate kidney issues, take 150 mg nirmatrelvir (one 150 mg tablet) and 100 mg ritonavir (one 100 mg tablet) together, twice daily for 5 days.

Warnings and Precautions

• Be cautious of potential severe drug interactions; review all medications before starting PAXLOVID.
• Discontinue immediately if significant allergic reactions like anaphylaxis occur.
• Liver issues such as elevated enzymes or jaundice have been reported in some cases using ritonavir.
• Using PAXLOVID might result in HIV-1 resistance for those with uncontrolled or undiagnosed HIV-1 infection.

Documentation & Availability in India:

If you are considering the import of Paxlovid (Nirmatrelvir & Ritonavir) to India, please be aware that Paxlovid can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

• Required Documentation for Import:
• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Paxlovid (Nirmatrelvir & Ritonavir) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Elahere in India: 

Paxlovid (Nirmatrelvir & Ritonavir) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Paxlovid can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Paxlovid (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Paxlovid (Nirmatrelvir & Ritonavir) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ’s

What is Paxlovid used for?

Paxlovid is utilized to treat mild-to-moderate cases of COVID-19 in adults who are at a high risk of developing severe illness or being hospitalized due to the virus.

How should Paxlovid be taken?

The recommended dosage is 300 mg of nirmatrelvir (two 150 mg tablets) along with 100 mg of ritonavir (one 100 mg tablet), taken together twice daily for 5 days, initiated within 5 days of experiencing COVID-19 symptoms.

Are there any precautions I should be aware of before taking Paxlovid?

Yes, it's crucial to review all medications with your healthcare provider before starting Paxlovid to avoid severe drug interactions. Additionally, discontinuation is necessary if significant allergic reactions occur.

Can Paxlovid cause any liver-related issues?

Some individuals using ritonavir, an element of Paxlovid, have experienced elevated liver enzymes or jaundice. Monitoring liver function may be recommended during treatment.

Who should avoid taking Paxlovid?

Paxlovid is not advised for individuals with a history of severe hypersensitivity reactions to its components or those taking specific medications susceptible to interactions with ritonavir.

Is Paxlovid FDA approved?

Yes

Arcalyst (Rilonacept)

• Medicine Name- Arcalyst 
• API- Rilonacept
• Strength- For injection: 220 mg of lyophilized powder in a single-dose vial for reconstitution
• Manufactured by- Kiniksa

Medicinal Uses

The interleukin-1 blocker ARCALYST (rilonacept) is prescribed for the following conditions in adults and children 12 years of age and older: 

Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).

Sustaining the remission of DIRA (Deficiency of Interleukin-1 Receptor Antagonist) in patients aged 10 years or older and in adults.

Treating adults and children 12 years of age and older for recurrent pericarditis (RP) and lowering their chance of recurrence

Recommended Dosage

• Administration:
• Given as a subcutaneous injection.
• For Conditions like CAPS, FCAS, MWS, and RP:

Adults:

• Loading Dose: 320 mg, two injections of 160 mg each.
• Maintenance Dose: 160 mg once weekly.
• Pediatric Patients (12 to 17 years):
• Loading Dose: 4.4 mg/kg (up to 320 mg), one or two injections.
• Maintenance Dose: 2.2 mg/kg (up to 160 mg) once weekly.

For DIRA:

Adults and Pediatric Patients (10 kg or more):

Dose: 4.4 mg/kg (up to 320 mg), one or two injections once weekly.

Patients should receive these injections as directed by their healthcare provider based on their age and specific condition.

Warning and Precautions:

Severe Infections: Patients using ARCALYST have reportedly experienced serious, sometimes fatal infections. In patients with ongoing or persistent infections, do not start ARCALYST medication. In the event that a patient gets a serious infection, stop treatment. 

Hypersensitivity Reactions: Stop giving ARCALYST and start the proper treatment if a hypersensitivity reaction happens. 

Vaccinations: Steer clear of live shots. As per current guidelines, update recommended vaccines prior to starting therapy.

Documentation & Availability in India:

If you are considering the import of Arcalyst (Rilonacept) to India, please be aware that Arcalyst can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Arcalyst (Rilonacept) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Arcalyst (Rilonacept)  in India: 

Arcalyst (Rilonacept) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Arcalyst (Rilonacept) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Arcalyst (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Arcalyst (Rilonacept) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What is the medicine ARCALYST used for?

ARCALYST (Rilonacept) is an interleukin-1 blocker prescribed for Cryopyrin-Associated Periodic Syndromes (CAPS), sustaining remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA), and treating recurrent pericarditis (RP) in adults and children 12 years and older.

What is the recommended dosage for ARCALYST?

The dosage varies for different conditions. For CAPS, FCAS, MWS, and RP, adults usually start with a loading dose of 320 mg, followed by a maintenance dose of 160 mg weekly. Pediatric patients follow weight-based dosing.

How is ARCALYST administered?

ARCALYST is administered as a subcutaneous injection.

Are there any warnings or precautions for ARCALYST use?

Yes, severe infections have been reported, and patients with ongoing infections should avoid starting ARCALYST. Hypersensitivity reactions may occur, and live vaccinations should be avoided during therapy.

What precautions are needed for the import of ARCALYST to India?

Import requires a valid prescription, diagnostic reports, and government-issued ID for the patient. An import permit, if applicable, is essential.

How can ARCALYST be ordered in India?

To order, a valid prescription and import permit are needed. The order will be confirmed upon receipt of these documents.

Is ARCALYST available in India?

Yes, ARCALYST is available in India through Indian Pharma Network (IPN), ensuring compliance with legal requirements and facilitating efficient delivery.

Orenitram (Treprostinil) price in india

• Medicine Name- Orenitram
• API- Treprostinil
• Strength- Extended-Release Tablets: 0.125 mg, 0.25 mg, 1 mg, 2.5 mg and 5 mg. 
• Manufactured by- United Therapeutics Corp.

Medicinal Uses:

A prostacyclin mimetic called orenitram is prescribed by the World Health Organization (WHO Group 1) to treat pulmonary arterial hypertension (PAH).

To enhance exercise capacity and postpone the advancement of the disease. The majority of patients with WHO functional class II–III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH linked to connective tissue disease (26%), respectively, were included in the studies that shown efficacy.

Recommended Dosage

• Administration Instructions:
• Take Orenitram with food.
• Swallow the tablets whole; do not crush or break them.

Initial Dosing:

Start with a dose of 0.125 mg three times a day (TID) or 0.25 mg twice a day (BID).

Titration:

• Adjust the dose by 0.125 mg TID or 0.25 mg or 0.5 mg BID.
• Titrate not more frequently than every 3 to 4 days, depending on tolerance.

Transition from IV or SC Remodulin®:

If switching from intravenous (IV) or subcutaneous (SC) Remodulin, increase the Orenitram dose while simultaneously decreasing the IV/SC infusion rate.

Mild Hepatic Impairment (Child Pugh Class A):

• Initiate at 0.125 mg BID.
• Increment at 0.125 mg BID not more frequently than every 3 to 4 days.

Moderate Hepatic Impairment:

Avoid using Orenitram in patients with moderate hepatic impairment.

Note: Patients should follow these instructions carefully, and any adjustments to the medication should be made under the guidance of their healthcare provider.

Warning and Precautions:

• Don't stop taking medication suddenly. (2.5, 5.1)
• Orenitram pills may become trapped in a diverticulum in people suffering from diverticulosis.

Documentation & Availability in India:

If you are considering the import of Orenitram (Treprostinil) to India, please be aware that Orenitram can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Orenitram (Treprostinil) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Orenitram (Treprostinil) in India: 

Orenitram (Treprostinil)  is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Orenitram (Treprostinil)  can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Orenitram (Treprostinil)

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Orenitram (Treprostinil) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What does a treprostinil injection indicate?

The injection of treprostinil is used to treat pulmonary arterial hypertension symptoms. This hypertension affects the major blood vessel that supplies the lungs with blood from the ventricle, the right side of the heart.

What kind of medication is treprostinil?

Treprostinil belongs to a group of drugs known as platelet-aggregation inhibitors and vasodilators. It improves blood flow by relaxing blood vessels, notably those in the lungs.

Which treprostinil formulations are available?

There are three different ways to take treprostinil: as an inhalation, subcutaneous, or intravenous solution. For PAH patients, each formulation is helpful.

What is the treprostinil brand name?

Treprostinil is a vasodilator used to treat pulmonary arterial hypertension. It is marketed under the names Tyvaso for inhalation, Orenitram for oral usage, and Remodulin for infusion.

What is treprostinil's bioavailability?

Treprostinil has an oral bioavailability of 17%, and four to six hours after oral administration, the medication concentration reaches its maximum value. Food has an impact on treprostinil's oral absorption.

Ayvakit (avapritinib) Price is India

• Medicine Name- Ayvakit 
• API- Avapritinib
• Strength- it is available as Tablets: 25 mg, 50 mg, 100 mg, 200 mg and 300 mg.
• Manufactured by- Blueprint Medicines Corporation

Medicinal Uses:

Gastrointestinal Stromal Tumor (GIST):

• AYVAKIT is indicated for the treatment of adults with unresectable or metastatic GIST.
• Specifically recommended for GIST cases harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including the challenging PDGFRA D842V mutations.

Advanced Systemic Mastocytosis (AdvSM):

• AYVAKIT is approved for the treatment of adult patients diagnosed with AdvSM.
• AdvSM includes various conditions such as aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), and mast cell leukemia (MCL).
• Limitations of Use for AdvSM: AYVAKIT is not recommended for patients with AdvSM having platelet counts less than 50 X 10^9 /L.

Indolent Systemic Mastocytosis (ISM):

• AYVAKIT is indicated for the treatment of adult patients diagnosed with Indolent Systemic Mastocytosis (ISM).
• Limitations of Use for ISM: AYVAKIT is not recommended for the treatment of patients with ISM having platelet counts less than 50 X 10^9 /L.

Note: Careful consideration of platelet counts is emphasized as a limitation of use for both AdvSM and ISM, ensuring the suitability of AYVAKIT in patients with platelet counts equal to or greater than 50 X 10^9 /L.

Recommended Dosage

Gastrointestinal Stromal Tumor (GIST):

• Patients should be selected for AYVAKIT treatment based on the presence of a PDGFRA exon 18 mutation.
• The recommended dosage for GIST is 300 mg orally once daily.

Advanced Systemic Mastocytosis (AdvSM):

• The recommended dosage for AdvSM is 200 mg orally once daily.
• Indolent Systemic Mastocytosis (ISM):

• The recommended dosage for ISM is 25 mg orally once daily.

Patients with Severe Hepatic Impairment (Child-Pugh Class C):

In cases of severe hepatic impairment (Child-Pugh Class C), the dose of AYVAKIT should be reduced. Specific guidance on dose reduction in this population should be determined based on clinical assessment and medical supervision.

Important Administration Instructions:

• AYVAKIT should be taken orally, with or without food.
• The medication should be swallowed whole with a glass of water.
• Patients should be educated on the importance of adhering to the prescribed dosage and administration schedule.

Note: Dosage adjustments and administration guidance for specific patient populations, such as those with severe hepatic impairment, should be made under the supervision of a healthcare professional, taking into account the patient's individual clinical condition and response to treatment. Regular monitoring may be necessary in such cases.

Warning and Precautions:

Intracranial Hemorrhage: Serious intracranial hemorrhage may occur; fatal events in less than 1% of patients. Monitor closely for risk factors: history of vascular aneurysm, prior intracranial hemorrhage, anticoagulant use, or thrombocytopenia. Symptoms: headache, nausea, vomiting, vision changes, altered mental status. Seek immediate medical attention.

Cognitive Effects: Cognitive adverse reactions in 33% of patients; manage with dose adjustments. Severity-dependent actions: continue at the same dose, resume at the same or reduced dose upon improvement, or permanently discontinue.

Platelet Counts and Thrombocytopenia: In AdvSM, platelet count monitoring essential. Perform every 2 weeks for the first 8 weeks, then adjust frequency based on platelet values.

Cognitive Effects in Specific Conditions: AYVAKIT patients may experience a wide range of cognitive adverse effects. Depending on the severity, patients with GIST, AdvSM, or ISM should continue taking AYVAKIT at the same dose, stop for a while and return at the same or lower dose when they feel better, or stop taking it permanently.

Photosensitivity: Photosensitivity reactions in 2.5% of patients. Advise limiting direct ultraviolet exposure during AYVAKIT treatment and for one week after discontinuation.

Embryo-Fetal Toxicity: AYVAKIT can cause fetal harm based on animal studies. Advise pregnant women of potential risk; use effective contraception during treatment and for 6 weeks after the final dose.

Documentation & Availability in India:

If you are considering the import of Ayvakit (avapritinib) to India, please be aware that Ayvakit can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Ayvakit (avapritinib) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Ayvakit (avapritinib) in India: 

Ayvakit (avapritinib) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Ayvakit (avapritinib) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Ayvakit (avapritinib)

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Ayvakit (avapritinib) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What is AYVAKIT, and what is it used for?

AYVAKIT is a kinase inhibitor used for treating unresectable or metastatic Gastrointestinal Stromal Tumor (GIST) with specific mutations, as well as Advanced Systemic Mastocytosis (AdvSM) and Indolent Systemic Mastocytosis (ISM).

How is AYVAKIT dosed for different conditions?

The dosage varies depending on the condition: 300 mg orally once daily for GIST, 200 mg for AdvSM, and 25 mg for ISM. In severe hepatic impairment, the AYVAKIT dose should be reduced.

What are the common side effects of AYVAKIT?

Common side effects include edema, nausea, fatigue, cognitive impairment, vomiting, and diarrhea, among others.

Are there any contraindications to using AYVAKIT?

No, there are no contraindications listed for AYVAKIT.

What precautions should be taken while using AYVAKIT?

Precautions include discontinuing AYVAKIT for intracranial hemorrhage, managing cognitive effects, advising about photosensitivity, and using effective contraception due to potential embryo-fetal toxicity.

Buy Voquezna Triple Pak online in india

• Voquezna Triple Pak  (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets)
• Medicine Name- vonoprazan, amoxicillin, clarithromycin 
• API- Vamorolone
• Manufactured by-  Phathom Pharmaceuticals, Inc.

Strength- 14 daily administration packs in a carton for morning and evening use, each containing one of the three medication products: Vonoprazan 20 mg tablets, Clarithromycin 500 mg tablets, and Amoxicillin 500 mg capsules

Medicinal Uses:

This co-packaged marvel is designed for the effective treatment of Helicobacter pylori (H. pylori) infection in adults.  Vonoprazan, a potent potassium-competitive acid blocker (PCAB), ensures relief from acid-related issues, promoting digestive comfort. Amoxicillin, a trusted penicillin-class antibacterial, steps in to combat bacterial intruders, bolstering your body's defense. Meanwhile, Clarithromycin, a robust macrolide antimicrobial, adds its strength to the mix, ensuring a comprehensive assault on the infection. Voquezna Triple Pak is your ally in the battle against H. pylori, offering a convenient and effective medicinal solution.

The suggested dosage is 20 mg of vonoprazan, 1,000 mg of amoxicillin, and 500 mg of clarithromycin, given twice a day, with or without meals, in the morning and evening (12 hours apart), for a total of 14 days.

Warning and Precautions:

Hypersensitivity Reactions: In rare cases, severe and potentially fatal reactions like anaphylaxis have been reported. If such reactions occur, discontinue Voquezna Triple Pak immediately and seek urgent medical attention.

Severe Cutaneous Adverse Reactions (SCAR): Cease medication at the first signs of SCAR or other hypersensitivity symptoms. Further evaluation may be necessary.

Clostridioides difficile-associated diarrhea (CDAD): Monitor for diarrhea during Voquezna Triple Pak treatment and consult healthcare providers if persistent.

Specific to Clarithromycin Component:

QT Prolongation: Avoid use in patients with known QT prolongation, ventricular arrhythmia, hypokalemia/hypomagnesemia, significant bradycardia, or those taking specific antiarrhythmics.

Hepatotoxicity: Discontinue if signs of hepatitis manifest.

Serious Adverse Reactions: Use caution with concomitant drugs due to potential interactions, especially with clarithromycin.

Embryo-Fetal Toxicity: Not recommended for pregnant women unless no alternative therapy is suitable.

Myasthenia Gravis: Exacerbation of myasthenia gravis has been reported; monitor patients accordingly.

These precautions aim to ensure patient safety and well-being during the course of Voquezna Triple Pak treatment. Always consult with healthcare professionals for personalized guidance.

Documentation & Availability in India:

If you are considering the import of Voquezna to India, please be aware that Voquezna can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

• Required Documentation for Import:
• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

• The order for Voquezna  will be confirmed upon the receipt of the following documents:
• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Voquezna  in India: 

Voquezna is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Voquezna can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Voquezna

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Voquezna in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Voquezna   from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What is Voquezna Triple Pak used for?

Voquezna Triple Pak is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. It contains vonoprazan, amoxicillin, and clarithromycin to combat the bacterial infection effectively.

How should I take Voquezna Triple Pak?

The recommended dosage is vonoprazan 20 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, twice daily (morning and evening, 12 hours apart), with or without food, for 14 days. Follow your healthcare provider's instructions carefully.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember. However, if it's close to the next scheduled dose, skip the missed one and continue with the regular dosing schedule.

Are there any potential side effects of Voquezna Triple Pak?

Like any medication, Voquezna Triple Pak may have side effects. Common ones include nausea, diarrhea, and headache. However, serious reactions can occur, so contact your healthcare provider if you experience any unusual symptoms.

Can I take other medications while on Voquezna Triple Pak?

Inform your healthcare provider about all medications, supplements, or herbal products you are taking. Some drugs may interact with Voquezna Triple Pak, potentially leading to adverse effects.

Is Voquezna Triple Pak safe during pregnancy?

The use of Voquezna Triple Pak during pregnancy is generally not recommended unless there are no alternative therapies. Pregnant individuals should consult their healthcare provider to assess potential risks and benefits.

Cibinqo (Abrocitinib) price in India

Abrocitinib

Medicine Name: Cibinqo 

API: Abrocitinib

Dosage Forms & Strengths: 50 mg, 100 mg, and 200 mg tablets

Manufactured by: ImmunoGen

Medicinal Uses

Abrocitinib is used to treat moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and above, who haven't responded well to other systemic drugs or when using those treatments isn't recommended.

Recommended Dosage:

• Starting Dose: Take 100 mg orally once daily.
• Adjustment: If the response is inadequate, the doctor may increase the dose to 200 mg daily.
• Special Situations: For moderate kidney issues or specific metabolic conditions, the dosage may be adjusted.
• Regular Check-ups: Regular check-ups and tests are needed to monitor your health during treatment.
• Precaution: Avoid using Abrocitinib with other JAK inhibitors or certain immunosuppressants.

Warnings and Precautions:

• Infections: Serious bacterial, fungal, or viral infections may occur. TB testing is required before and during treatment.
• Mortality Risk: Some patients have a higher risk of all-cause mortality, including cardiovascular complications.
• Cancer Risk: Instances of lymphomas and lung cancers have been reported.
• Heart and Blood Clot Risks: Issues like heart problems and blood clots have occurred in some cases.

Documentation & Availability in India:

If you are considering the import of Abrocitinib to India, please be aware that Abrocitinib can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

A valid prescription from a qualified medical practitioner.

Diagnostic reports of the patient.

Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Abrocitinib will be confirmed upon the receipt of the following documents:

A valid prescription from a qualified doctor.

An import permit, if applicable.

Availability of Abrocitinib in India: 

Abrocitinib is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Abrocitinib can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Abrocitinib (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Abrocitinib in India and to initiate the ordering process, please reach out to us through the following contact details:

Phone: +91-9310090915

Toll-Free Number: 1800-889-1064

Email: info@indianpharmanetwork.in

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Abrocitinib from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ’s

What is Abrocitinib used for?

Abrocitinib is used to treat moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and above when other systemic drugs haven't worked or are not recommended.

How should I take Abrocitinib?

The typical starting dose is 100 mg orally once daily. Your doctor may adjust this to 200 mg daily if the initial response is inadequate. Specific dosage adjustments might apply in certain health conditions.

What should I be cautious about while taking Abrocitinib?

It's essential to avoid using Abrocitinib with other JAK inhibitors or specific immunosuppressants. Additionally, regular health check-ups and tests are necessary during treatment.

Are there any significant risks associated with Abrocitinib?

Yes, serious infections (bacterial, fungal, or viral), increased mortality risk, potential for developing cancers like lymphomas and lung cancers, and risks related to heart problems and blood clots have been observed in some cases.

Do I need any specific tests before or during Abrocitinib treatment?

Yes, it's crucial to undergo TB testing before and during treatment due to the risk of serious infections. Regular health monitoring will also be necessary to ensure your safety during the course of treatment.

Toripalimab : Metastatic Nasopharyngeal Carcinoma

 According to a randomized trial, "Adding the investigational PD-1 immune checkpoint inhibitor toripalimab to standard frontline chemotherapy significantly helps in order to delay the disease progression in patients with the recurrent/metastatic nasopharyngeal carcinoma.

Outcomes from the phase-III JUPITER-2 trial demonstrated that the addition of toripalimab significantly improved the progression-free survival (PFS) in comparison to placebo, with a median 11.7 months in comparison to 8.0 months (HR 0.52, 95 percent CI 0.36 to 0.74, P=0.0003), reported Rui-Hua Xu, MD, PhD, of the Sun Yat-Sen University Cancer Center in Guangzhou in China. 

Speaking at a press briefing in advance of the virtual American Society of Clinical Oncology (ASCO) annual meeting, Xu said, "In an interim analysis of overall survival (OS), toripalimab plus gemcitabine/cisplatin also demonstrated benefit over placebo."

"The combination was safe, and no new safety signals were noted," he added. "The outcomes favor the use of toripalimab together with the gemcitabine-cisplatin regimen as the new standard of care for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Nasopharyngeal carcinoma (NPC), is the most common cancer originating in nasopharynx, most commonly in the postero-lateral nasopharynx or pharyngeal recess (fossa of Rosenmüller), accounting for 50% of cases. Nasopharyngeal carcinoma occurs in children and adults. This carcinoma significantly differs from other existing cancers of the head and neck in its occurrence, causes, clinical nature, and treatment. NPC is vastly more common in East Asia and Africa than elsewhere, with viral, dietary and genetic factors implicated in its causation. 

Although the current standard first-line treatment for the recurrent or metastatic nasopharyngeal carcinoma is gemcitabine-cisplatin chemotherapy, the duration of the response is typically less than 6 months.

Toripalimab, a monoclonal antibody specific for PD-1, is approved in China as a monotherapy in the 2'nd or 3'rd-line setting, where it has demonstrated durable responses in patients with recurrent/metastatic disease.

In JUPITER-2, a total of 289 patients receiving gemcitabine-cisplatin in the first-line setting were randomized 1:1 to either toripalimab or placebo. Patients were treated with chemo plus toripalimab or placebo every 3 weeks for up to 6-cycles, followed by the toripalimab or placebo every 3 weeks until disease progressed.

The 1-year progression-free survival rate was 49.4% in the toripalimab arm compared with 27.9% in the placebo arm. The overall survival rates at 2 years were noted as 77.8% with toripalimab vs 63.3% with placebo.

Regarding safety, the incidence of grade ≥3 adverse events (AEs) was identical in both the arms (89.0% for the toripalimab patients and 89.5% for the placebo group), Xu reported. 

The rate of adverse events leading to the interruption of treatment was also identical (7.5% vs 4.9%, respectively), as were fatal adverse events (2.7% vs 2.8%, respectively). Immune-related adverse events, however, were significantly higher in the toripalimab arm (39.7% vs 18.9%), as were immune-related grade ≥3 adverse events (7.5% vs 0.7%).

American Society of Clinical Oncology Chief Medical Officer and Executive Vice President Julie R. Gralow, MD, commented at the briefing that while treatment advances for the nasopharyngeal carcinoma have lagged behind those of other cancers.

Toripalimab got the breakthrough designation by the (FDA) Food and Drug Administration for the recurrent/metastatic nasopharyngeal carcinoma, fast track and orphan drug status for the certain other types of cancer.

With Food and Drug Administration approval these findings should be proved to be practice changing," Julie R. Gralow said.

Reference: https://www.onclive.com/view/frontline-toripalimab-plus-gemcitabine-cisplatin-significantly-improves-pfs-in-recurrent-or-metastatic-nasopharyngeal-carcinoma